Compare ESPR & DAKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ESPR | DAKT |
|---|---|---|
| Founded | 2008 | 1968 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Office Equipment/Supplies/Services |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 731.9M | 1.0B |
| IPO Year | 2013 | 1996 |
| Metric | ESPR | DAKT |
|---|---|---|
| Price | $2.10 | $19.20 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $7.60 | N/A |
| AVG Volume (30 Days) | ★ 5.7M | 403.2K |
| Earning Date | 05-05-2026 | 03-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 60.71 | N/A |
| EPS | N/A | ★ 0.75 |
| Revenue | $403,135,000.00 | ★ $608,932,000.00 |
| Revenue This Year | $1.53 | $12.94 |
| Revenue Next Year | N/A | $8.32 |
| P/E Ratio | ★ N/A | $25.67 |
| Revenue Growth | ★ 21.31 | 6.89 |
| 52 Week Low | $0.73 | $11.97 |
| 52 Week High | $4.18 | $28.27 |
| Indicator | ESPR | DAKT |
|---|---|---|
| Relative Strength Index (RSI) | 32.00 | 37.52 |
| Support Level | $1.02 | $18.64 |
| Resistance Level | $2.99 | $19.38 |
| Average True Range (ATR) | 0.20 | 0.71 |
| MACD | -0.03 | 0.10 |
| Stochastic Oscillator | 6.26 | 9.32 |
Esperion Therapeutics Inc is a commercial-stage biopharmaceutical company currently focused on bringing new medicines to patients that address unmet medical needs. It has developed and is commercializing U.S. Food and Drug Administration, or FDA, approved oral, once-daily, non-statin medicines for patients who are at risk for cardiovascular disease (or CVD and are struggling with elevated low-density lipoprotein cholesterol, or LDL-C. The Company views its operations and manages its business in one operating segment, which is the business of researching, developing, and commercializing therapies for the treatment of patients with elevated LDL-C. The company depends almost entirely on the success of two products, the bempedoic acid tablet and the bempedoic acid/ezetimibe combination tablet.
Daktronics Inc designs and manufactures electronic scoreboards, programmable display systems, and large-screen video displays for sporting, commercial, and transportation applications. It is engaged in a full range of activities: marketing and sales, engineering and product design and development, manufacturing, technical contracting, professional services, and customer service and support. The company offers a complete line of products, from small scoreboards and electronic displays to large multimillion-dollar video display systems as well as related control, timing, and sound systems. The company has five reportable segments: Commercial, Live Events, High School Park and Recreation, Transportation, and International. The company makes the majority of its revenue from Live events.